Article Details

Avidity Biosciences Aims to Sell $100M in Shrs to Fund AOC 1001 Trial

Retrieved on: 2021-08-02 20:25:28

Tags for this article:

Click the tags to see associated articles and topics

Avidity Biosciences Aims to Sell $100M in Shrs to Fund AOC 1001 Trial. View article details on hiswai:

Excerpt

... 1/2 clinical trial of AOC 1001, an antibody designed to reduce levels of DMPK, the disease-related mRNA, in patients with myotonic dystrophy.

Article found on: www.marketwatch.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up